

The following is an examiner's statement of reasons for allowance:

Amendments to the specification are acknowledged. A review of the deletions as well as inaccurate data does not raise new issues and thus will be entered. It is noted that many of the preparations involve alternate procedures. The change to n-butanol in Description 10 is agreed is not new matter in view of the description of said solvent as preferred on p.8. Uses present in newly presented claims are not subject to any 112 rejections based on references newly cited by applicants and the examiner.

Claims directed to Alzheimer's Disease are no longer rejected based on the type of compounds being claimed which share the same basic core with a compound in clinical trials as reported by applicants in the newly cited IDS.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

/Emily Bernhardt/

Primary Examiner, Art Unit 1624

Application/Control Number: 10/571,405  
Art Unit: 1624

Page 3